Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Background technique [0002] Semaglutide, a long-acting GLP-1 analog developed by Nove Nordisk for subcutaneous injection once a week, was approved by the US FDA on December 5, 2017
Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research
Quality and stability study results The reduced glutathione for injection prepared in the above examples 1 to 4 was taken, and the quality and stability thereof were investigated, TABLE 1 quality comparison table As can be seen from the above table, the reduced glutathione for injection prepared in the above examples has the required properties, the pH values of all batches of samples before and after freeze-drying are basically consistent, the reduced glutathione for injection prepared in example 3 has a lower loss on drying, and the reduced glutathione for injection prepared in example 1 has a higher loss on drying
Vial Size 3
US$ 29.57
US$ 20.41
US$ 27.64
US$ 21.14
US$ 26.57
